KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Eli Lilly (LLY) over the last 14 years, with Q4 2025 value amounting to $899.3 million.

  • Eli Lilly's Shares Outstanding (Diluted Average) fell 53.09% to $899.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $899.3 million, marking a year-over-year decrease of 53.09%. This contributed to the annual value of $899.3 million for FY2025, which is 53.09% down from last year.
  • Latest data reveals that Eli Lilly reported Shares Outstanding (Diluted Average) of $899.3 million as of Q4 2025, which was down 53.09% from $899.7 million recorded in Q3 2025.
  • Eli Lilly's 5-year Shares Outstanding (Diluted Average) high stood at $912.4 million for Q1 2021, and its period low was $899.3 million during Q4 2025.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $904.8 million, with a median of $904.2 million in 2024.
  • In the last 5 years, Eli Lilly's Shares Outstanding (Diluted Average) tumbled by 78.98% in 2022 and then increased by 21.04% in 2024.
  • Quarter analysis of 5 years shows Eli Lilly's Shares Outstanding (Diluted Average) stood at $911.7 million in 2021, then dropped by 0.77% to $904.6 million in 2022, then dropped by 0.15% to $903.3 million in 2023, then increased by 0.09% to $904.1 million in 2024, then decreased by 0.53% to $899.3 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $899.3 million for Q4 2025, versus $899.7 million for Q3 2025 and $900.2 million for Q2 2025.